New hope for teens with rare bleeding disorder: experimental drug enters final testing
NCT ID NCT07194850
First seen Jun 27, 2026 · Last updated Aug 13, 2026 · Updated 4 times
Summary
This study tests an IV drug called efgartigimod in teens aged 12 to 18 with chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bruising and bleeding. The goal is to find the right dose and see if it safely raises platelet counts. Participants first receive either the drug or a placebo for up to 24 weeks, then everyone gets the drug for up to two years.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC THROMBOCYTOPENIC PURPURA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
A.O.U. Citta della Salute e della Scienza di Torino - Ospedale Infantile Regina Margherita
RECRUITINGTorino, 10126, Italy
-
Bambino Gesu Children's Hospital
RECRUITINGRoma, 165, Italy
-
Cardiff and Vale NHS Trust - University Hospital of Wales (UHW)
RECRUITINGCardiff, CF14 4XW, United Kingdom
-
Centre Hospitalier Universitaire de Bordeaux Groupe Hospitalier Pellegrin Hopital des Enfants
RECRUITINGBordeaux, 33000, France
-
Charite - Universitaetsmedizin Berlin - Campus Virchow-Klinikum (CVK)
RECRUITINGBerlin, 13353, Germany
-
Fondazione IRCCS San Gerardo dei Tintori
RECRUITINGMonza, 20900, Italy
-
Gaslini Children's Hospital
RECRUITINGGenoa, 16147, Italy
-
Hospital Infantil Universitario Nino Jesus (HIUNJS)
RECRUITINGMadrid, 28009, Spain
-
Hospital Materno-Infantil Universitario Gregorio Maranon
RECRUITINGMadrid, 28009, Spain
-
Hospital Sant Joan de Deu Barcelona
RECRUITINGEsplugues de Llobregat, 08950, Spain
-
Hospital Universitari Vall d'Hebron
RECRUITINGBarcelona, 08035, Spain
-
Hospital Universitario 12 de Octubre
RECRUITINGMadrid, 28041, Spain
-
Institute Of Mother And Child Healthcare Of Serbia Dr Vukan Cupic
RECRUITINGBelgrade, 11070, Serbia
-
Institutul Clinic Fundeni
RECRUITINGBucharest, 022328, Romania
-
Royal Manchester Children's Hospital - Manchester University NHS Foundation Trust
RECRUITINGManchester, M139WL, United Kingdom
-
Samodzielny Publiczny Zaklad Opieki Zdrowotnej Uniwersytecki Szpital Kliniczny nr 4
RECRUITINGLodz, 92-213, Poland
-
The Royal Hospital for Children - Glasgow Health Board
RECRUITINGGlasgow, G51 4TF, United Kingdom
-
Universitaetsklinikum Freiburg Kinder - Kinder- und Jugendklinik
RECRUITINGFreiburg im Breisgau, 79106, Germany
-
University Clinical Centre of Kragujevac
RECRUITINGKragujevac, 34000, Serbia
-
Uniwersytecki Szpital Dzieciecy w Lublinie
RECRUITINGLublin, 20-093, Poland
-
Vilnius University Hospital Santaros Klinikos, Children's Hospital
RECRUITINGVilnius, 8406, Lithuania
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an RNA 'Message' reprogram the immune system to stop autoimmune blood disorders?
- Can a bispecific antibody tame two autoimmune blood disorders?
- Can a gut bacteria transplant help when steroids fail for a bleeding disorder?
- Can a new drug calm the immune System's attack on blood cells?
- Could a simple blood test predict lupus in children with ITP?
- Will a new drug form work the same? study tests two versions of SKI-O-703